<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00915967</url>
  </required_header>
  <id_info>
    <org_study_id>IRB_5170</org_study_id>
    <nct_id>NCT00915967</nct_id>
  </id_info>
  <brief_title>Prevention of Neurosurgical Wound Infections</brief_title>
  <acronym>POWI</acronym>
  <official_title>Pilot Project: Prevention of Neurosurgical Wound Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to determine whether injecting the antibiotic vancomycin directly
      into surgical wounds can decrease the rate of infection following implantation of
      neurosurgical devices.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 13, 2009</start_date>
  <completion_date type="Actual">December 19, 2014</completion_date>
  <primary_completion_date type="Actual">December 19, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Infection That Requires Removal of the Neurosurgical Device</measure>
    <time_frame>Six months post-operation</time_frame>
    <description>The primary outcome was infection that required removal of the implanted device within 6 months of surgery. At our institution all patients with evidence of hardware infection have the entire stimulation/pump system removed. Subjects were either seen in clinic or reached by telephone more than 6 months after surgery and assessed for whether they had had infection requiring hardware removal or any superficial infection requiring additional post-operative antibiotics.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">214</enrollment>
  <condition>Surgical Wound Infections</condition>
  <arm_group>
    <arm_group_label>Vancomycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the experimental group will receive Vancomycin injected directly into the wound pocket.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in the saline group will receive a Saline injection directly into the wound pocket.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>Subjects randomized to the vancomycin group will receive an injection (up to 10 mL) of 5 mg/mL vancomycin administered directly into the wound with a blunt needle following watertight fascial closure.</description>
    <arm_group_label>Vancomycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Saline Solution)</intervention_name>
    <description>Subjects randomized to the saline group will receive an injection (up to 10 mL) of saline solution directly into the wound following watertight fascial closure.</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  deep brain stimulators (DBS)

          -  spinal cord stimulators (SCS)

          -  motor cortex stimulators (MCS)

          -  vagus nerve stimulators (VNS)

          -  peripheral nerve stimulators (PNS)

        Exclusion Criteria:

          -  allergies to vancomycin

          -  immunocompromise or taking immunosuppressant drugs

          -  currently taking aminoglycoside antibiotics, such as amikacin, gentamicin, neomycin,
             streptomycin or tobramycin

          -  diagnosed renal failure

          -  currently undergoing chemotherapy

          -  pregnancy

          -  non-english speakers

          -  unable to return for follow-up, or unable to be contacted by telephone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim J Burchiel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurological Surgery, Oregon Health &amp; Science University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Valerie C Anderson, PhD, MCR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurological Surgery, Oregon Health &amp; Science University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen T Magill, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>School of Medicine, Oregon Health &amp; Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital, Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Miller JP, Acar F, Burchiel KJ. Significant reduction in stereotactic and functional neurosurgical hardware infection after local neomycin/polymyxin application. J Neurosurg. 2009 Feb;110(2):247-50.</citation>
    <PMID>19263587</PMID>
  </reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>June 5, 2009</study_first_submitted>
  <study_first_submitted_qc>June 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2009</study_first_posted>
  <results_first_submitted>January 17, 2019</results_first_submitted>
  <results_first_submitted_qc>April 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 30, 2019</results_first_posted>
  <last_update_submitted>April 8, 2019</last_update_submitted>
  <last_update_submitted_qc>April 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Kim J. Burchiel</investigator_full_name>
    <investigator_title>Kim J. Burchiel, MD / John Raaf Professor and Chairman, Department of Neurological Surgery</investigator_title>
  </responsible_party>
  <keyword>Infection</keyword>
  <keyword>Vancomycin</keyword>
  <keyword>Neurosurgery</keyword>
  <keyword>Stimulator</keyword>
  <keyword>Pump</keyword>
  <keyword>Deep Brain Stimulation</keyword>
  <keyword>Intrathecal Pump</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Wound Infection</mesh_term>
    <mesh_term>Surgical Wound Infection</mesh_term>
    <mesh_term>Surgical Wound</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>214 subjects signed consent. 198 subjects were enrolled.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Vancomycin</title>
          <description>Subjects in the experimental group will receive Vancomycin injected directly into the wound pocket.
Vancomycin: Subjects randomized to the vancomycin group will receive an injection (up to 10 mL) of 5 mg/mL vancomycin administered directly into the wound with a blunt needle following watertight fascial closure.</description>
        </group>
        <group group_id="P2">
          <title>Saline</title>
          <description>Subjects in the saline group will receive a Saline injection directly into the wound pocket.
Placebo (Saline Solution): Subjects randomized to the saline group will receive an injection (up to 10 mL) of saline solution directly into the wound following watertight fascial closure.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vancomycin</title>
          <description>Subjects in the experimental group will receive Vancomycin injected directly into the wound pocket.
Vancomycin: Subjects randomized to the vancomycin group will receive an injection (up to 10 mL) of 5 mg/mL vancomycin administered directly into the wound with a blunt needle following watertight fascial closure.</description>
        </group>
        <group group_id="B2">
          <title>Saline</title>
          <description>Subjects in the saline group will receive a Saline injection directly into the wound pocket.
Placebo (Saline Solution): Subjects randomized to the saline group will receive an injection (up to 10 mL) of saline solution directly into the wound following watertight fascial closure.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="98"/>
            <count group_id="B2" value="100"/>
            <count group_id="B3" value="198"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Least Squares Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="100"/>
                    <count group_id="B3" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="55" upper_limit="71"/>
                    <measurement group_id="B2" value="64" lower_limit="54" upper_limit="74"/>
                    <measurement group_id="B3" value="63.5" lower_limit="54" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="100"/>
                    <count group_id="B3" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="100"/>
                    <count group_id="B3" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Infection That Requires Removal of the Neurosurgical Device</title>
        <description>The primary outcome was infection that required removal of the implanted device within 6 months of surgery. At our institution all patients with evidence of hardware infection have the entire stimulation/pump system removed. Subjects were either seen in clinic or reached by telephone more than 6 months after surgery and assessed for whether they had had infection requiring hardware removal or any superficial infection requiring additional post-operative antibiotics.</description>
        <time_frame>Six months post-operation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vancomycin</title>
            <description>Subjects in the experimental group will receive Vancomycin injected directly into the wound pocket.
Vancomycin: Subjects randomized to the vancomycin group will receive an injection (up to 10 mL) of 5 mg/mL vancomycin administered directly into the wound with a blunt needle following watertight fascial closure.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Subjects in the saline group will receive a Saline injection directly into the wound pocket.
Placebo (Saline Solution): Subjects randomized to the saline group will receive an injection (up to 10 mL) of saline solution directly into the wound following watertight fascial closure.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Infection That Requires Removal of the Neurosurgical Device</title>
          <description>The primary outcome was infection that required removal of the implanted device within 6 months of surgery. At our institution all patients with evidence of hardware infection have the entire stimulation/pump system removed. Subjects were either seen in clinic or reached by telephone more than 6 months after surgery and assessed for whether they had had infection requiring hardware removal or any superficial infection requiring additional post-operative antibiotics.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>The study aimed to determine whether retrospectively observed decrease in infection rate could be attributed to the addition of local antibiotics A prospective, randomized, double-blind, placebo-controlled pilot study comparing standard antibiotic prophylaxis with addition of local intrawound injection of vancomycin or placebo, was designed.
Study Procedures were standard of care, risk was minimal</desc>
      <group_list>
        <group group_id="E1">
          <title>Vancomycin</title>
          <description>Subjects in the experimental group will receive Vancomycin injected directly into the wound pocket.
Vancomycin: Subjects randomized to the vancomycin group will receive an injection (up to 10 mL) of 5 mg/mL vancomycin administered directly into the wound with a blunt needle following watertight fascial closure.</description>
        </group>
        <group group_id="E2">
          <title>Saline</title>
          <description>Subjects in the saline group will receive a Saline injection directly into the wound pocket.
Placebo (Saline Solution): Subjects randomized to the saline group will receive an injection (up to 10 mL) of saline solution directly into the wound following watertight fascial closure.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>Wound Infection</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Trials</name_or_title>
      <organization>Oregon Health &amp; Science University</organization>
      <phone>503-494-4314</phone>
      <email>nsgclinicalresearch@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

